Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide does both — and the two effects are closely connected. Appetite suppression is the mechanism; weight loss is the result. In the STEP 1 trial, adults taking semaglutide 2.4mg lost an average of around 15% of their body weight over 68 weeks, which is a meaningful difference from appetite reduction alone. That said, understanding why the weight comes off matters, because it changes how you eat and move while you're on treatment. Wegovy (semaglutide) is a prescription-only medicine, so a prescriber assesses whether it's appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Largely, yes, and that's not a limitation, it's the mechanism. Semaglutide is a GLP-1 receptor agonist: it mimics a gut hormone that tells the brain you've had enough, slows the rate at which food leaves the stomach, and reduces the urgency you'd normally feel around mealtimes. The practical effect is that most people find they're satisfied with smaller portions and think about food less between meals.
That shift in appetite produces a sustained calorie deficit, which is what leads to actual fat loss over weeks and months. The medicine doesn't directly metabolise fat or burn energy at a cellular level in the way some people imagine. What it does is make the deficit easier to maintain, the constant pull of hunger that undermines most conventional diets is substantially reduced for many people on treatment.
There's also evidence that semaglutide influences food preferences, with some people reporting less interest in high-calorie foods. The mechanism behind that isn't fully characterised yet, but it's one reason the overall effect tends to exceed what simple portion reduction would predict on its own. You can read more about how Wegovy affects appetite in detail if you want to dig into the pharmacology.
This is a question our prescribers hear regularly, and the honest answer is nuanced. Wegovy doesn't trigger fat burning directly. What it produces is a consistent energy gap, you consume fewer calories than your body needs, so it draws on stored energy, including fat. The weight that comes off is therefore genuine fat loss, but the medicine's role is in creating the right conditions rather than accelerating the burning process itself.
One important distinction: because semaglutide reduces overall intake, some people lose muscle alongside fat if they're not eating enough protein or staying active. This is why clinical guidance consistently pairs treatment with a reduced-calorie diet that's protein-adequate, alongside increased physical activity. What you eat on semaglutide is not a minor footnote, it meaningfully shapes the quality of the weight you lose, not just the amount.
The STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average body-weight reduction over 68 weeks in adults without diabetes taking semaglutide 2.4mg weekly alongside lifestyle changes. That's a figure drawn from a placebo-controlled setting, so it reflects the medicine's contribution on top of diet and activity, not appetite suppression alone. The fat versus appetite question is explored in more depth on a dedicated page if you'd like the full picture.
This is where the appetite-versus-weight distinction becomes practically important. Because semaglutide works through an active biological mechanism, appetite typically returns toward its previous level once treatment stops. Clinical follow-up data from the STEP programme showed that a significant proportion of lost weight is regained within a year of stopping without ongoing lifestyle support in place.
That doesn't mean treatment is futile, far from it. It means the medicine works while it's working, and that the lifestyle habits built during treatment (eating patterns, portion awareness, activity) carry real value beyond the prescription. Some people use the reduced-appetite period to reset their relationship with food in ways that hold. Others need longer-term treatment. Which applies to you is a clinical conversation, not something to guess at. You can read more about Wegovy as a treatment overall, including how it fits into a longer weight-management plan.
If you're weighing up whether an injection or a daily tablet suits you better, the treatment overview covers the options licensed in the UK right now.
Because the weight loss comes from eating less rather than from a direct metabolic boost, the quality of what you do eat carries more weight than usual, literally. A smaller daily intake that's low in protein and fibre will produce weight loss but risks muscle loss and fatigue. Most people on semaglutide feel full quickly, so every meal becomes a smaller opportunity to get nutrients in.
Practical priorities tend to be: protein at every meal (to preserve muscle), plenty of water (GI side effects are more common when dehydrated), and enough fibre to support digestion without worsening nausea. Many people find that eating three smaller, structured meals (rather than grazing) works better with the appetite changes that semaglutide produces. A rough meal framework built around these principles can make a real difference; the semaglutide meal plan guidance covers practical approaches in detail, and what to eat on Wegovy gives meal-by-meal ideas.
The NHS notes that weight-management medicines work best alongside a reduced-calorie diet and increased activity, that framing matters even when appetite falls naturally. For a broader look at cost and access if you're considering treatment, the Wegovy private prescription page explains what's involved. One transparent price at nume covers consultation, prescription, delivery and aftercare, no separate fees stacked on top. Current treatment pricing is shown on our treatment page.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.